Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BRD3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BRD3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BRD3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/BRD3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/BRD3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BRD3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRD3 | SNV | Missense_Mutation | rs780729968 | c.731N>A | p.Arg244Gln | p.R244Q | Q15059 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | novel | c.1637C>T | p.Ala546Val | p.A546V | Q15059 | protein_coding | tolerated(0.29) | benign(0.028) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | novel | c.1391N>T | p.Ala464Val | p.A464V | Q15059 | protein_coding | deleterious(0.05) | benign(0.051) | TCGA-AX-A3FS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | novel | c.1280C>T | p.Ala427Val | p.A427V | Q15059 | protein_coding | tolerated(0.53) | benign(0) | TCGA-B5-A0JU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | | c.1928N>G | p.Lys643Arg | p.K643R | Q15059 | protein_coding | tolerated(0.06) | benign(0.437) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | | c.523N>C | p.Ser175Pro | p.S175P | Q15059 | protein_coding | tolerated(0.13) | probably_damaging(0.91) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | rs201977681 | c.539C>T | p.Ala180Val | p.A180V | Q15059 | protein_coding | tolerated(0.23) | benign(0.007) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | novel | c.484G>A | p.Gly162Arg | p.G162R | Q15059 | protein_coding | tolerated(0.19) | benign(0.309) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRD3 | SNV | Missense_Mutation | | c.338N>G | p.Tyr113Cys | p.Y113C | Q15059 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
BRD3 | SNV | Missense_Mutation | novel | c.443N>C | p.Leu148Ser | p.L148S | Q15059 | protein_coding | tolerated(0.76) | possibly_damaging(0.611) | TCGA-BK-A13B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ABBV-744 | ABBV-744 | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ALPRAZOLAM | ALPRAZOLAM | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PMID26924192-Compound-102 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | ESTAZOLAM | ESTAZOLAM | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 252827533 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | PMID26924192-Compound-104 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | Pyrrolo-pyrrolone derivative 1 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 187051822 | | |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | | L-655708 | CHEMBL52030 | 22137933 |
8019 | BRD3 | ENZYME, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, SERINE THREONINE KINASE, TRANSCRIPTION FACTOR | inhibitor | 404859011 | | |